Evotec SE has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of $20 million to Evotec. A target-based program has progressed into late pre-clinical development, further contributing to the pipeline of discovery to clinical-stage programs in neurodegeneration that the partnership has generated.   Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify dise...